10 active not recruiting, 8 completed, 7 recruiting, 6 terminated. 21 Phase 2, 10 Phase 1, 4 Phase 3, 2 Not applicable.
Follow Carcinosarcoma: new trials by email Literature Review of Carcinosarcoma trials Research Report on Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial Aerobic Exercise, Biospecimen Collection, Dietary Intervention - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 90 | 2026-10-10 | 2026-07-23 |
| A Study of PHST001 in Advanced Solid Tumors PHST001, Paclitaxel, Topotecan - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Recruiting | Pheast Therapeutics | 426 | 2025-03-31 | 2026-10-05 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring Oncological Follow-up - Stage I Testicular Seminoma, Stage I Testicular Nonseminomatous Germ Cell Tumor | Phase 2 | Recruiting | Centre Oscar Lambret | 88 | 2024-02-28 | 2026-03-18 |
| ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer Atezolizumab, ONC201 - Endometrial Cancer, Metastasis | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 58 | 2023-10-23 | 2026-01-29 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer Biospecimen Collection, Diagnostic Imaging Testing, Excisional Biopsy - Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 428 | 2022-12-07 | 2026-11-06 |
| (VELA) Study of BLU-222 in Advanced Solid Tumors BLU-222, Carboplatin, Ribociclib - Advanced Solid Tumors, HR+ Breast Cancer | Phase 1 | Terminated | Blueprint Medicines Corporation | 50 | 2022-04-07 | 2025-11-28 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma Camrelizumab Combined With Apatinib - PD-1 Immunotherapy, VEGFR-TKI | Phase 2 | Unknown | Fudan University | 45 | 2021-11-21 | 2022-03-04 |
| Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma Ovarian Cancer, High Grade Serous Carcinoma | Unknown | Liz-Anne Lewsley | 250 | 2021-10-27 | 2022-09-23 | |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-11-12 |
| Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus. Image-guided adjuvant pelvic radiotherapy - Endometrioid Adenocarcinoma, Serous Carcinoma | Not applicable | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 23 | 2020-08-26 | 2025-08-01 |
| ZW25 in Women With Endometrial Cancers ZW25 - Endometrial Cancer, Carcinosarcoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 16 | 2020-08-12 | 2025-05-22 |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer Biospecimen Collection, Brachytherapy, Computed Tomography - Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 164 | 2020-04-09 | 2026-07-02 |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes Rucaparib - Solid Tumor | Phase 2 | Terminated | pharmaand GmbH | 83 | 2020-01-16 | 2023-10-02 |
| ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss Ceralasertib, Olaparib, Durvalumab - Gynaecological Cancers | Phase 2 | Active not recruiting | Institute of Cancer Research, United Kingdom | 174 | 2019-11-27 | 2026-02-20 |
| Nivolumab for Recurrent/Metastatic Carcinosarcoma nivolumab - Recurrent/Metastatic Carcinosarcoma | Phase 2 | Unknown | Yonsei University | 28 | 2019-11-13 | 2022-02-04 |
Showing 20 of 39. Sign in to see all of them.
Endometrial Neoplasms (18) · Ovarian Neoplasms (11) · Fallopian Tube Neoplasms (7) · Leiomyosarcoma (6) · Neoplasm Metastasis (6) · Breast Neoplasms (5) · Uterine Cervical Neoplasms (5) · Uterine Neoplasms (5) · Carcinoma, Endometrioid (4) · Colorectal Neoplasms (4) · Esophageal Neoplasms (4) · Sarcoma (4) · Stomach Neoplasms (4) · Adenocarcinoma, Clear Cell (3)
Neoplasms by Histologic Type (39) · Neoplasms, Complex and Mixed (39) · Neoplasms, Connective and Soft Tissue (39) · Neoplasms (36) · Sarcoma (35) · Neoplasms by Site (29) · Female Urogenital Diseases (28) · Female Urogenital Diseases and Pregnancy Complications (28) · Genital Diseases (28) · Genital Diseases, Female (28) · Genital Neoplasms, Female (28) · Urogenital Diseases (28) · Urogenital Neoplasms (28) · Uterine Diseases (20) · Uterine Neoplasms (18)
Specimen Handling (10) · Paclitaxel (8) · Biopsy (6) · Carboplatin (6) · Magnetic Resonance Spectroscopy (6) · Nivolumab (5) · X-Rays (3) · olaparib (3) · pembrolizumab (3) · Fluorouracil (2) · Gemcitabine (2) · Immunoglobulin G (2) · Taxes (2) · cediranib (2) · ceralasertib (2)
National Cancer Institute (NCI) (7) · Leap Therapeutics, Inc. (2) · Mayo Clinic (2) · Memorial Sloan Kettering Cancer Center (2) · AGO Study Group (1) · Aristotle University Of Thessaloniki (1) · Australia New Zealand Gynaecological Oncology Group (1) · Blueprint Medicines Corporation (1) · Centre Oscar Lambret (1) · Deciphera Pharmaceuticals, LLC (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fudan University (1) · GOG Foundation (1) · Incyte Corporation (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1)
United States (24) · Canada (5) · United Kingdom (5) · South Korea (4) · Germany (3) · Italy (2) · Puerto Rico (2) · Brazil (1) · China (1) · France (1) · Greece (1) · Guam (1) · Japan (1)
Alexander Mustea, Prof. Dr. med. (1) · Alison Freimund (1) · Camila MV Moniz, Doctor (1) · Claire Friedman, MD (1) · Cynthia Sirard (1) · David D'Souza, M.D. (1) · Dev Mukhopadhyay, PhD (1) · Domenica Lorusso, Prof. (1) · Edward J Tanner (1) · Emmanouil Papanastasiou, Dr. (1) · Floor Backes (1) · Gordon Jayson (1) · Helen J Mackay (1) · Iain McNeish (1) · Joyce F Liu (1)
PMID 10655437, PMID 11063636, PMID 11304695, PMID 11479630, PMID 15350372, PMID 15721404, PMID 16271748, PMID 17290061, PMID 17395252, PMID 17822748, PMID 17936342, PMID 18378136, PMID 18755503, PMID 23397080, PMID 23410977, PMID 25341582, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34340209, PMID 34380663, PMID 34716198, PMID 34904813, PMID 35007153, PMID 35288469, PMID 36972022, PMID 37001446, PMID 37411031, PMID 38127487, PMID 38243705, PMID 38262242, PMID 38358334, PMID 38431043, PMID 38653864, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40044930, PMID 40402690, PMID 40588371, PMID 40632975, PMID 40791544, PMID 40966692, PMID 41484629, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42339309
U10CA180868 (4), 2016 (1), 2018 (1), 2023 (1), R21CA267584 (1), U10CA027469 (1), U10CA180888 (1), UG1CA189867 (1), UM1CA186644 (1), UM1CA186688 (1), UM1CA186709 (1)